Tulip tablets 40mg, no. 30

primary hypercholesterolemia (heterozygous familial and nonfamilial hypercholesterolemia (type II according to Frederickson);

combined (mixed) hyperlipidemia (types IIa and IIb according to Frederickson);

dysbetalipoproteinemia (type III according to Frederickson) (as an addition to the diet);

familial endogenous hypertriglyceridemia (type IV according to Frederickson), resistant to diet;

homozygous familial hypercholesterolemia with insufficient effectiveness of diet therapy and other non-pharmacological treatments;

prevention of cardiovascular diseases:

- primary prevention of cardiovascular complications in patients without clinical signs of ischemic heart disease, but with several risk factors for its development: age over 55 years, nicotine addiction, arterial hypertension, diabetes mellitus, low level of HDL-C in blood plasma, genetic predisposition, including h.on the background of dyslipidemia;

- secondary prevention of cardiovascular complications in patients with coronary artery disease in order to reduce the total mortality rate, myocardial infarction, stroke, re-hospitalization for angina pectoris and the need for revascularization.

Before starting treatment with AtorisЃ, the patient should be transferred to a lipid-lowering diet, which must be followed during drug therapy.

Inside, regardless of food intake, once (at any time of the day, but at the same time), every day.

The recommended starting dose is 10 mg daily. The dose of the drug varies from 10 mg to 80 mg once a day and is selected taking into account the initial level of LDL-C, the goal of therapy and the individual therapeutic effect.

The therapeutic effect of AtorisЃ develops after 2 weeks of taking the drug, and the maximum effect is achieved after 4 weeks. Therefore, the dose should not be changed earlier than 4 weeks after starting the drug.

In primary (heterozygous hereditary and polygenic) hypercholesterolemia (type IIa) and mixed hyperlipidemia (type IIb), treatment begins with an initial dose of 10 mg 1 time per day, which is increased after 4 weeks, depending on the patient's response. The maximum daily dose is 80 mg.

With homozygous hereditary hypercholesterolemia, the initial dose is selected individually, depending on the severity of the disease. When using a maximum daily dose of 80 mg (once), the most optimal effect was noted.

AtorisЃ is used as an adjunctive therapy to other methods of treatment (plasmapheresis) or as the main treatment if therapy with other methods is not possible.

For elderly patients, as well as with kidney disease, dose adjustment is not required.

For patients with impaired liver function, the drug is prescribed with caution due to the slowdown in its excretion from the body. In this situation, monitoring of clinical and laboratory parameters is necessary, and if significant pathological changes are detected, the dose should be reduced, or treatment should be discontinued.

hypersensitivity to any component of the drug;

active liver disease (including active chronic hepatitis, chronic alcoholic hepatitis);

liver failure;

cirrhosis of the liver of any etiology;

an increase in the activity of hepatic transaminases of unknown origin by more than 3 times compared with VGN;

skeletal muscle disease;

pregnancy and lactation, as well as use in women of reproductive age who do not use adequate methods of contraception;

age up to 18 years (efficacy and safety of use have not been established);

galactosemia (because the drug contains lactose) or glucose / galactose malabsorption syndrome, lactase deficiency.

With care: alcoholism, history of liver disease.